Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type.

导出 OA

翻译打印收藏纠错

作者： Lorraine,Dalens ^[1] ; Julie,Lecuelle ^[2] ; Laure,Favier ^[2] ; Cléa,Fraisse ^[3] ; Aurélie,Lagrange ^[4] ; Courèche,Kaderbhai ^[5] ; Romain,Boidot ^[1] ; Sandy,Chevrier ^[1] ; Hugo,Mananet ^[1] ; Valentin,Derangère ^[1] ; Caroline,Truntzer ^[6] ; François,Ghiringhelli ^[6]

作者单位： Department of Medical Oncology, Georges François Leclerc Cancer Center-UNICANCER, 21000 Dijon, France. ^[1] UFR des Sciences de Santé, University of Burgundy-Franche-Comté, 21000 Dijon, France. ^[2] Platform of Transfer in Biological Oncology, Georges-Francois Leclerc Cancer Center-UNICANCER, 21000 Dijon, France. ^[3] UMR INSERM 1231, 21000 Dijon, France. ^[4] Genomic and Immunotherapy Medical Institute, Dijon University Hospital, 21000 Dijon, France. ^[5] Department of Biopathology, Georges François Leclerc Cancer Center-UNICANCER, 21000 Dijon, France. ^[6]

关键词 TCR TMB biomarkers exome sequencing immunotherapy

主题词人类(Humans);癌, 非小细胞肺(Carcinoma, Non-Small-Cell Lung);肺肿瘤(Lung Neoplasms);突变(Mutation);基因组学(Genomics);免疫疗法(Immunotherapy)

DOI 10.3390/ijms24087592

PMID 37108755

发布时间 2023-05-01

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交